國立虎尾科技大學 |

Lung Cancer and Personalized Medicine = Current Knowledge and Therapies /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Lung Cancer and Personalized Medicine/ edited by Aamir Ahmad, Shirish Gadgeel.
其他題名:	Current Knowledge and Therapies /
其他作者:	Ahmad, Aamir.
面頁冊數:	XIII, 228 p. 26 illus., 14 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer research. -
電子資源:	https://doi.org/10.1007/978-3-319-24223-1
ISBN:	9783319242231

Lung Cancer and Personalized Medicine = Current Knowledge and Therapies /
Lung Cancer and Personalized MedicineCurrent Knowledge and Therapies /[electronic resource] :edited by Aamir Ahmad, Shirish Gadgeel. - 1st ed. 2016. - XIII, 228 p. 26 illus., 14 illus. in color.online resource. - Advances in Experimental Medicine and Biology,8930065-2598 ;. - Advances in Experimental Medicine and Biology,889.

1 Lung Cancer Statistics -- 2 Epidemiology of Lung Cancer -- 3 Lung Cancer In Never Smokers -- 4 Immune Therapy -- 5 Anti-angiogenesis in personalized therapy of lung cancer -- 6 Target therapy in Lung Cancer -- 7 Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: an update -- 8 KRAS-Mutant Lung Cancers in the Era of Targeted Therapy -- 9 Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer -- 10 Chemotherapy Resistance in Lung Cancer -- 11 Current state of metal-based drugs for the efficient therapy of lung cancers and lung metastases.

This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.

ISBN: 9783319242231

Standard No.: 10.1007/978-3-319-24223-1doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Lung Cancer and Personalized Medicine = Current Knowledge and Therapies /
LDR:02962nam a22004095i 4500 001 980896
003 DE-He213
005 20200706071950.0
007 cr nn 008mamaa
008 201211s2016 gw | s |||| 0|eng d
020 $a 9783319242231 $9 978-3-319-24223-1
024 7 $a 10.1007/978-3-319-24223-1 $2 doi
035 $a 978-3-319-24223-1
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Lung Cancer and Personalized Medicine $h [electronic resource] : $b Current Knowledge and Therapies / $c edited by Aamir Ahmad, Shirish Gadgeel.
250 $a 1st ed. 2016.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a XIII, 228 p. 26 illus., 14 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 893
505 0 $a 1 Lung Cancer Statistics -- 2 Epidemiology of Lung Cancer -- 3 Lung Cancer In Never Smokers -- 4 Immune Therapy -- 5 Anti-angiogenesis in personalized therapy of lung cancer -- 6 Target therapy in Lung Cancer -- 7 Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: an update -- 8 KRAS-Mutant Lung Cancers in the Era of Targeted Therapy -- 9 Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer -- 10 Chemotherapy Resistance in Lung Cancer -- 11 Current state of metal-based drugs for the efficient therapy of lung cancers and lung metastases.
520 $a This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.
650 0 $a Cancer research. $3 1253664
650 0 $a Molecular biology. $3 583443
650 0 $a Internal medicine. $3 644638
650 0 $a Oncology . $3 1253469
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Molecular Medicine. $3 668353
650 2 4 $a Internal Medicine. $3 668583
650 2 4 $a Oncology. $3 593951
700 1 $a Ahmad, Aamir. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1072728
700 1 $a Gadgeel, Shirish. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1103674
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319242217
776 0 8 $i Printed edition: $z 9783319242224
776 0 8 $i Printed edition: $z 9783319795928
830 0 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 889 $3 1253792
856 4 0 $u https://doi.org/10.1007/978-3-319-24223-1
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)